Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) is one of the stocks highlighted in Jim Cramer’s latest Mad Money recap as he provided top stock insights. Answering a caller’s query about the stock, Cramer said: Too risky for me. I just think that at this stage, with this market, that one you could lose too much money. I’m very sorry. A laptop and a computer monitor display a detailed stock market technical analysis chart. Photo by Jakub Zerdzicki on Pexels Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) is a cli ...

Core Insights - Paradigm Biocapital Advisors increased its stake in Olema Pharmaceuticals by purchasing 750,000 shares in Q4 2025, valued at approximately $13.35 million based on quarter-end pricing [1][2] - Olema Pharmaceuticals' market capitalization is currently $1.2 billion, with a share price of $14.08, reflecting a 242% increase over the past year, significantly outperforming the S&P 500's 15% gain [4][7] Company Overview - Olema Pharmaceuticals is a clinical-stage biotechnology company focused on developing targeted therapies for women's cancers, particularly estrogen receptor antagonists for breast cancer [5][8] - The company utilizes a proprietary drug discovery platform and its lead program, OP-1250, is aimed at treating estrogen receptor-positive breast cancer [5][8] Financial Position - Olema has over $500 million in cash at year-end and recently raised $200 million, positioning the company well for upcoming pivotal moments in its clinical trials [6][7] - The recent buy by Paradigm raised its position in Olema to approximately 4.5% of its reportable assets under management (AUM) as of December 31, 2025 [7] Upcoming Catalysts - Olema is approaching critical Phase 3 data expected later this year, with multiple pipeline readouts scheduled for 2026, which are crucial for its future success [6][9] - The company primarily targets oncologists, healthcare providers, and patients affected by hormone-driven cancers, focusing on the oncology therapeutics market [8]

Core Viewpoint - Olema Pharmaceuticals, Inc. (OLMA) has experienced significant selling pressure, resulting in a 33.4% decline in stock price over the past four weeks, but analysts anticipate improved earnings in the near future [1] Group 1: Technical Analysis - The stock is currently in oversold territory with a Relative Strength Index (RSI) reading of 27.66, indicating a potential reversal in trend [5] - RSI is a momentum oscillator that helps identify whether a stock is oversold, typically when the reading falls below 30 [2][3] Group 2: Fundamental Indicators - Analysts have raised earnings estimates for OLMA by 1.1% over the last 30 days, suggesting a positive outlook for price appreciation [7] - OLMA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks, indicating strong potential for a turnaround [8]

Core Insights - Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on targeted therapies for breast cancer and will present two preclinical posters at the AACR Annual Meeting in April 2026 [1][2] Group 1: Poster Presentation Details - The first poster titled "Palazestrant directly recruits the corepressor protein NCoR1 in vitro leading to complete antagonism of estrogen receptor alpha" will be presented on April 20, 2026, from 2:00-5:00pm PT [2] - The second poster titled "Palazestrant, a CERAN, in combination with OP-3136, a KAT6 inhibitor, synergistically downregulates cell proliferation and metastasis related gene signatures" will also be presented on April 20, 2026, from 2:00-5:00pm PT [2] Group 2: Company Overview - Olema Oncology is committed to transforming the standard of care for patients with breast cancer, advancing a pipeline of novel therapies based on a deep understanding of endocrine-driven cancers [3] - The lead product candidate, palazestrant (OP-1250), is currently in two Phase 3 clinical trials and is a proprietary, orally available complete estrogen receptor antagonist and selective estrogen receptor degrader [3][4] - OP-3136, another candidate, is a potent KAT6 inhibitor currently in a Phase 1 clinical study, having shown significant anti-proliferative activity in ER+ breast cancer models [5]

Financial Performance - Olema's net losses were $162.5 million and $129.5 million for the years ended December 31, 2025 and 2024, respectively, with an accumulated deficit of $597.6 million as of December 31, 2025 [581]. - The company has not generated any revenue from product sales and does not expect to do so for the foreseeable future [586]. - Net loss for the year ended December 31, 2025 was $162.5 million, compared to a net loss of $129.5 million in 2024, indicating an increase of $32.9 million [600]. - The company has incurred significant operating losses and negative cash flows, with net losses of $162.5 million and $129.5 million for the years ended December 31, 2025 and 2024, respectively [605]. - Total operating expenses for 2025 were $178.7 million, compared to $142.3 million in 2024, resulting in a loss from operations of $178.7 million [600]. - Net cash used in operating activities for the year ended December 31, 2025 was $146.716 million, compared to $104.351 million for 2024 [625]. - The company reported a net loss of $162.5 million for the year ended December 31, 2025, primarily due to $157.7 million in research and development expenses [626]. Research and Development - Research and development expenses are expected to increase substantially as Olema advances its lead product candidate, palazestrant, and its second candidate, OP-3136, through clinical trials [592]. - Research and development expenses for the year ended December 31, 2025 were $157.7 million, an increase of $33.2 million from $124.5 million in 2024, primarily due to increased spending on clinical operations and a $5.0 million milestone payment to Aurigene [602]. - The pivotal Phase 3 clinical trial of palazestrant, OPERA-01, was initiated in November 2023, with top-line results anticipated in fall 2026 and potential NDA submission in 2027 [576]. - Olema is also conducting a Phase 1 study for OP-3136, with the first clinical data expected in the second quarter of 2026 [578]. - The execution of the OPERA-02 trial, which combines palazestrant with ribociclib, is supported by a collaboration agreement with Novartis, with top-line data expected in 2028 [577]. - The company expects to incur significant expenses and operating losses for the foreseeable future as it advances clinical development, necessitating additional capital for operations [614]. Financial Position and Funding - As of December 31, 2025, the company had $505.4 million in cash, cash equivalents, and marketable securities, with an accumulated deficit of $597.6 million [606]. - The company completed a follow-on public offering on November 19, 2025, selling 11,500,000 shares at a price of $19.00 per share, resulting in net proceeds of $204.8 million [613]. - As of December 31, 2025, the company expects cash, cash equivalents, and marketable securities to fund its operating plan through mid-2028 [618]. - The company has material cash requirements totaling $3.0 million under its Credit Facility and $1.241 million in operating leases due within one year [619]. - The company has potential future milestone payments of up to $45.0 million in clinical development and regulatory milestones, and up to $370.0 million in commercial milestones under the Aurigene Agreement [619]. - The company anticipates financing its cash needs through equity offerings, debt financings, collaborations, and licensing arrangements [623]. - Net cash provided by financing activities in 2025 was $211.297 million, mainly from a follow-on public offering [631]. - As of December 31, 2025, the company had cash, cash equivalents, and marketable securities of $505.4 million, an increase from $434.1 million in 2024 [641]. - The company had an outstanding long-term borrowing of $3.0 million under its Credit Facility as of December 31, 2025 [642]. Administrative Expenses - Olema's general and administrative expenses are expected to increase as the company expands its headcount and enhances its IT infrastructure to support future commercialization efforts [597]. - General and administrative expenses for the year ended December 31, 2025 were $21.0 million, up from $17.7 million in 2024, reflecting higher corporate and personnel-related costs [603]. Company Classification - The company qualifies as a "smaller reporting company" due to annual revenue being less than $100.0 million in 2025 [638].

On-track to report top-line data in the fall of 2026 from the pivotal Phase 3 OPERA-01 trial of palazestrant as a monotherapy in patients with 2/3L ER+/HER2- metastatic breast cancerAdvanced enrollment in the OPERA-02 pivotal Phase 3 trial of palazestrant in combination with ribociclib in patients with frontline ER+/HER2- metastatic breast cancer Initiated the Phase 1b/2 study of palazestrant in combination with Pfizer’s novel CDK4 inhibitor, atirmociclib, in patients with ER+/HER2- metastatic breast cancer ...

Core Viewpoint - Roche's persevERA trial has failed, but the frontline opportunity for palazestrant is not considered eliminated by H.C. Wainwright [1] Summary by Relevant Categories Trial Outcomes - The persevERA trial results are described as "disappointing" [1] - The failure of the persevERA trial is not seen as a complete readthrough to Olema Oncology's OPERA-02 trial [1] Investment Perspective - H.C. Wainwright maintains a Buy rating on Olema shares, indicating confidence in the company's prospects despite the trial outcome [1] - The analyst suggests that differences in combination agents could favor the OPERA-02 trial, which is evaluating palazestrant plus ribociclib [1]

Core Viewpoint - Olema Pharmaceuticals Inc. is focused on developing targeted therapies for women's cancers, particularly breast cancer, with its leading project being Palazestrant, a new class of treatments [1][4] Company Overview - Olema Pharmaceuticals Inc. is a biopharmaceutical company dedicated to women's cancer therapies, with strategic collaborations with pharmaceutical giants like Pfizer Inc. and Novartis AG [1][4] - The company's leading project, Palazestrant, is a complete estrogen receptor antagonist and selective estrogen receptor degrader [1] Stock Performance - On March 9, 2026, H.C. Wainwright set a price target of $38 for Olema, indicating a potential upside of approximately 69% from a trading price of $16.45 [2] - The stock has recently declined to $16.30, marking a decrease of 24.36% from its previous price, attributed to disappointing results from Roche Holdings AG's phase 3 study [2] - Olema's stock has shown significant volatility, with a trading range over the past year between $2.86 and $36.26, and a market capitalization of approximately $1.28 billion [3][4]

LOS ANGELES--(BUSINESS WIRE)--Olema Pharmaceuticals, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – OLMA. ...

Olema Pharmaceuticals Inc. (NASDAQ:OLMA) stock is trading lower on Monday, in reaction to data from Roche Holdings AG’s (OTC:RHHBY) phase 3 persevERA Breast Cancer study of giredestrant combined with palbociclib in advanced cancer patients. • Olema Pharmaceuticals stock is feeling bearish pressure. Why are OLMA shares down?The study did not meet its primary objective of a statistically significant improvement in progression-free survival versus letrozole plus palbociclib.The study showed a numerical improve ...